Special Communication  |   September 2008
Statins and Sepsis: Good Bullet, Disappearing Target
Author Notes
  • Address correspondence to Richard H. Woerndle, DO, Chief Intensivist, Southeastern Regional Medical Center, 300 W 27th St, Lumberton, NC 28358-3075.E-mail: 
Article Information
Cardiovascular Disorders / Preventive Medicine
Special Communication   |   September 2008
Statins and Sepsis: Good Bullet, Disappearing Target
The Journal of the American Osteopathic Association, September 2008, Vol. 108, 486-490. doi:10.7556/jaoa.2008.108.9.486
The Journal of the American Osteopathic Association, September 2008, Vol. 108, 486-490. doi:10.7556/jaoa.2008.108.9.486

Despite several decades of research and phenomenal advances in technology and therapeutics, sepsis remains a catastrophic enigma. As a frequent cause of death, sepsis now rivals acute myocardial infarction. The longstanding therapeutic principles of early antibiotics use and supportive care have been difficult to improve upon. The authors conducted a concise review of pertinent literature on the pathophysiologic mechanisms of sepsis and the pharmacologic effects of statins. They conclude that, though statins possess anti-inflammatory and lipid-lowering properties, these effects may not be advantageous throughout the changing immunoresponse that can occur in sepsis syndrome. Based on the available information, statin therapy seems advantageous before the onset of sepsis and during sepsis resolution—but not during the compensatory anti-inflammatory response that may occur. Thus, the authors recommend that, until the status of a patient's changing immune response can be clearly determined, the uninterrupted use of statin therapy throughout the full spectrum of sepsis should be avoided.

In the United States, there were an estimated 750,000 cases of severe sepsis in 1995, resulting in 215,000 deaths,1 and there was an annualized increase in the incidence of sepsis of 8.7% between 1979 and 2000.2 Sepsis now rivals acute myocardial infarction as a frequent cause of death. It is the leading cause of death in noncoronary intensive care units (ICUs).3 
The early use of antibiotics and supportive care are long-standing therapeutic principles for patients with sepsis and have been difficult to improve upon. In large clinical trials of patients with sepsis, hemodynamic optimization,4 low-volume ventilation,5 low-dose glucocorticoid therapy for patients with a suboptimal response to adrenocorticotropin,6 and “tight” glucose control for patients who have had surgery7 have each demonstrated significant, albeit small, reductions in mortality. Recombinant human-activated protein C has been found to produce favorable results in the most severely ill patients, but it may actually be detrimental to patients whose illnesses are less severe.8 
When seeking easy solutions to complex medical problems, we sometimes find “silver bullets.” Examples include aspirin for reducing cardiovascular risk, angiotensin-converting enzyme (ACE) inhibitors for managing left ventricular systolic dysfunction, and glucocorticoids for managing reactive airway disease. However, just as a villain must exist before a hero can arise, a clear pathologic target must be known before an effective silver bullet can emerge. In the case of sepsis, the “clear target” remains elusive. 
There has been much interest in using 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (ie, statins) for sepsis. Therefore, we conducted a concise review of pertinent literature on the pathophysiologic mechanisms of sepsis and the pharmacologic effects of statins using the National Library of Medicine's PubMed database and other sources. Keywords included compensatory anti-inflammatory syndrome, HMG-CoA reductase inhibitors, sepsis, septic shock, and statins. This review allowed us to speculate on the effectiveness of statin therapy as an adjunct to sepsis management. 
Statins: Good Anti-Inflammatory Bullet
In addition to lowering serum lipids and decreasing cardiovascular risk, statins have been shown to have anti-inflammatory effects.9 Subsequently, speculation has increased as to the beneficial effects of statins in managing sepsis.10,11 
In animal studies, improvement in mortality has been demonstrated in sepsis models with administration of the statin simvastatin.12,13 In humans with atherosclerotic disease, administration of a statin significantly reduced the risk of subsequent septic events, including severe and fatal sepsis, according to Hackam et al.14 A list of these and other pharmacologic effects of statins in individuals with sepsis, as indicated by the pertinent literature, is presented in Figure 1. 
Published studies on patients with infections—though limited in design, number, and scope—have suggested a net positive effect of prior or concomitant statin prescription. Almog et al15 reported on 361 consecutive patients admitted to a medical service with acute bacterial infection. Within this group, 82 patients (23%) were treated with a statin before admission.15 Severe sepsis occurred in 3% of statin-treated patients, compared with 19% of patients not receiving prior statin therapy.15 
For patients with documented bacteremia, Liappis et al16 and Kruger et al17 found a notable decrease in mortality in patients taking statins before hospitalization, compared with patients not taking statins before hospitalization. It should be noted, however, that the number of critically ill patients in each report was small. Within the statin groups, only 6 patients in the Liappis et al16 report and 10 patients in the Kruger et al17 report required ICU admission. 
Fernandez et al18 reported on 438 patients who required ICU admission and mechanical ventilatory support. These patients were at high risk of ICU-acquired infections. Within this group, 38 patients (9%) received statin therapy before ICU admission and continued with this regimen throughout hospitalization.18 Statin-treated patients had 61% mortality versus 42% mortality for patients not receiving statins.18 
In the only long-term study of patients with bacteremia who were receiving concomitant statin therapy, Thomsen et al19 found no short-term (0-30 d) advantage—but significantly improved long-term (30-180 d) survival—in patients using statins before, during, and after hospitalization, compared with patients not using statins (8.4% mortality in statin users vs 17.5% mortality in nonusers; adjusted mortality rate ratio, 0.44; 95% confidence interval, 0.24-0.80).19 The beneficial effects of statin therapy in this group may have been related to a decrease in cardiovascular events after inflammatory episodes. An association between acute infection and a transient increase in cardiovascular ischemic events was documented by Smeeth et al,20 who reported that statins may exert a protective effect in patients with these conditions by decreasing inflammation and blood thrombogenic properties. 
Although in vitro studies do not always translate into beneficial in vivo effects,21 an extensive accumulation of data has resulted from in vitro studies as to possible physiologic mechanisms of statins' anti-inflammatory effects. This research has found that statins reduce the elevations of cytokine tumor necrosis factor α (TNF-α) after a lipopolysaccharide challenge.22 
Statins also inhibit leukocyte function antigen-1 (LEA-1; also known as CD11a/CD18), which is involved in T-cell activation and leukocyte recirculation and migration to inflammatory sites.23 Other research has shown that lipopolysaccharide inhibition of acetylcholine,24 norepinephrine,24 and phenylephrine13 is blocked in the presence of a statin, allowing these agents to result in vasoconstriction. Antioxidant properties of statins include the inhibition of superoxide production via the nicotinamide adenine dinucleotide phosphate oxidase system in monocytes,25 neutrophils,26 and endothelial cells.27 Statin administration has also been found to inhibit the production of nitric oxide, a potent endothelial cell–derived vasodilator that may cause vasopressor-resistant vasodilatation.28 
Figure 1.
The pharmacologic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (ie, statins), as indicated by the literature cited.
Figure 1.
The pharmacologic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (ie, statins), as indicated by the literature cited.
Other Anti-Inflammatory Bullets
From the 1970s through the early 1990s, the prevailing concept of sepsis was one of a runaway inflammatory cascade that culminated in multiorgan failure and death.29-32 Subsequent research endeavors focused on inflammatory targets. 
Several pharmacologic agents were developed based on this concept, but these agents have failed to demonstrate clear, beneficial clinical responses.32-35 Among these anti-inflammatory agents are antiprostacyclins,36 antiendotoxin antibodies,37 bradykinin antagonists,38 glucocorticoids,39 interleukin receptor antagonists,40 monoclonal antibodies to LEA-1 (CD11a/CD18),41 nitric oxide synthase inhibitors,42 platelet-activating factor antagonists,43 soluble TNF receptors,44 and TNF antagonists.45,46 In addition, some of these agents have even been found to have detrimental effects in patients with sepsis.34,44 
Disappearing Target
The inability to develop an anti-inflammatory agent with clear clinical benefit for patients with sepsis has led to the concept that sepsis is much more complex and variable than previously believed, making for a very elusive target. Natanson et al35 wrote in 1994, “Perhaps our therapeutic premise has been flawed: Attempting to block the harmful effects of inflammatory mediators may not produce a net benefit [in patients with sepsis] because it may also compromise host defense and ultimately worsen outcome.” Natanson et al35 suggested that there is variability in the host response to infection, such as an excessive inflammatory response, immunocompetence, or immunocompromise. The concept of a compensatory anti-inflammatory response syndrome was developed by Bone et al,39,47 who suggested that an initial intense inflammatory reaction occurs in individuals with sepsis, followed by an immunosuppressed state or downregulation of the immune response. This decrease in immune response, if not recovered, may result in death.39,47 The findings of Natanson et al,35 Bone et al,39,47 and others demonstrate the complex, variable nature of sepsis. Sometimes it is referred to as the “sepsis syndrome” (Figure 2). 
Several mechanisms of immunosuppression in sepsis have been investigated. Among the research findings related to these mechanisms are the following: 
  • Activated CD4+ T cells can proceed toward distinctly diverging forms of cytokine expression. Type 1 helper T cells produce the inflammatory cytokines TNF-α, IFN-γ, and IL-2. Type 2 helper T cells produce anti-inflammatory IL-4 and IL-10. Patient survival is improved when an exaggerated response by type 2 helper T cells is normalized.48,49 Elevated levels of IL-10 can indicate patient mortality.49,50
  • Apoptosis via intrinsic proteases occurs at a markedly accelerated rate in patients with sepsis.51 Apoptotic cells induce an anergic state in surviving lymphocytes, furthering the anti-inflammatory condition.52
  • Monocyte anergy also occurs in patients with sepsis, including down modulation of monocyte human leukocyte antigen-DR53 and granulocyte-macrophage colony-stimulating factor.54
Good Bullet, Wrong Target
Statins are effective at lowering lipid levels, but lipids are the wrong target in sepsis. Higher lipid levels are desirable in these patients. 
Lipid levels decrease markedly in patients with sepsis and critical illness, with lipoprotein concentrations falling to 50% of recovery values in most cases.55,56 Concentrations of low-density lipoprotein cholesterol are at a nadir at the time of diagnosis of severe sepsis, and concentrations of high-density lipoprotein cholesterol reach nadir by day 3 after diagnosis.57 Low lipid levels associated with sepsis—or related to surgery or trauma—may be caused by increased use of the cholesterol substrate for new cell synthesis and repair, according to Engelberg.58 Exogenous cholesterol is required for cell development and growth because intrinsic synthesis of cellular cholesterol cannot meet these needs.58 Exogenous cholesterol is also required to maintain the fluidity and microviscosity of cell walls.58 These cholesterol functions affect the linkage of membrane transport with receptor and enzymatic activities. 
Figure 2.
The complex, variable characteristics of sepsis, also referred to as the “sepsis syndrome” and the “compensatory anti-inflammatory response syndrome.”
Figure 2.
The complex, variable characteristics of sepsis, also referred to as the “sepsis syndrome” and the “compensatory anti-inflammatory response syndrome.”
Research has shown that hypocholesterolemia in critical illness and multisystem organ failure correlates with decreased patient survival rates.56,59 Lipoproteins have been found to bind with and neutralize bacterial endotoxins.60-62 The binding of lipopolysaccharides on the CD14 receptors of monocytes and macrophages results in the production and release of cytokines.63,64 Competition for lipopolysaccharide binding between CD14 receptors and lipoproteins is dependent on lipoprotein availability, as noted by Netea et al.65 As increasing levels of lipoproteins become available, lipopolysaccharide-lipoprotein interaction and neutralization predominate, resulting in an attenuated release of cytokines.65 These data60-65 suggest that serum lipoproteins bind lipopolysaccharides, neutralizing them in a concentration-dependent manner. 
These and other observations have led to investigations of the effects of lipid-infusion therapy in patients with sepsis.66,67 Favorable results of lipid-infusion therapy have been noted in some animal studies.66,67 Results from human studies on lipid-infusion therapy were not available at the time the present study was prepared. 
When to Shoot
A review of the literature indicates that sepsis is a condition of dynamic response with great variability. Statins clearly possess anti-inflammatory and lipid-lowering properties, but these effects may not remain relevant within the variable continuum of sepsis syndrome. Anti-inflammatory therapies may prove advantageous in cases of excessive inflammatory response, but such therapies may be counterproductive in situations where immunosuppression predominates. Serum lipids also provide essential cellular substrates in times of tremendous demand and dwindling reserves of cholesterol, which is reduced by statins. Furthermore, any process that neutralizes bacterial endotoxins would seem favorable. Thus, based on the available information, statin therapy seems advantageous in patients before the onset of sepsis and during sepsis resolution, but perhaps not when patients are critically ill. 
Ongoing research efforts to develop a means of identifying excessive and potentially detrimental fluctuations in the immune response—whether inflammatory or immune suppressive in nature—may direct statin therapy toward its most effective use. If an excessive inflammatory response is detected, anti-inflammatory agents, including statins, could prove advantageous at that point in the etiologic process. If a transition toward an immunosuppressive state is detected during continued patient monitoring, a change in pharmacologic therapy may be warranted, with deletion of the anti-inflammatory agents. 
Until the status of a patient's changing immune response can be clearly determined, an uninterrupted use of statin therapy throughout the spectrum of sepsis syndrome should be avoided. In summation, we have good pharmacologic “bullets” for sepsis. We just need to know when to “shoot” them. 
 At the time of manuscript submission, Dr Woerndle was a fellow in critical care at Pontiac Osteopathic Hospital Medical Center in Mich, where Dr Maxwell was program director.
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303-1310.
Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546-1554.
Guidet B, Aegerter P, Gauzit R, Meshaka P, Dreyfuss D; CUB-Réa Study Group. Incidence and impact of organ dysfunctions associated with sepsis. Chest. 2005;127:942-951. Available at: Accessed August 22, 2008.
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368-1377.
Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000;342:1301-1308.
Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288:862-871.
van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359-1367.
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J. Anti-inflammatory and immunomodulatory effects of statins [review]. Kidney Int. 2003;63:12-23.
Corona A, Raimondi F, Singer M. Statin use and mortality in the bacteremic critically ill patient. Crit Care Med. 2006;34:1270-1272.
Warnholtz A, Genth-Zotz S, Munzel T. Should treatment of sepsis include statins [editorial]? Circulation. 2005;111:1735-1737. Available at: Accessed August 22, 2008.
Merx MW, Liehn EA, Janssens U, Lutticken R, Schrader J, Hanrath P, et al. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis [published online ahead of print May 3, 2004]. Circulation. 2004;109:2560-2565. Available at: Accessed August 22, 2008.
Giusti-Paiva A, Martinez MR, Felix JV, da Rocha MJ, Carnio EC, Elias LL, et al. Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats. Shock. 2004;21:271-275.
Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet. 2006;367:413-418.
Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, et al. Prior statin therapy is associated with a decreased rate of severe sepsis [published online ahead of print August 2, 2004]. Circulation. 2004;110:880-885. Available at: Accessed August 22, 2008.
Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia [published online ahead of print September 20, 2001]. Clin Infect Dis. 2001;33:1352-1357. Available at: Accessed August 29, 2007.
Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteraemia [published online ahead of print November 10, 2005]. Intensive Care Med. 2006;32:75-79.
Fernandez R, De Pedro VJ, Artigas A. Statin therapy prior to ICU admission: protection against infection or a severity marker [published online ahead of print August 16, 2005]? Intensive Care Med. 2006;32:160-164.
Thomsen RW, Hundborg HH, Johnsen SP, Pedersen L, Sørensen HT, Schønheyder HC, et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med. 2006;34:1080-1086.
Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611-2618.
Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002;22:300-305. Available at: Accessed August 22, 2008.
Inoue K, Takano H, Yanagisawa R, Sakurai M, Yoshikawa T. Statin, inflammation, and sepsis [letter]. Chest. 2004;125:2365. Available at: Accessed August 22, 2008.
Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7:687-692.
Pleiner J, Schaller G, Mittermayer F, Zorn S, Marsik C, Polterauer S, et al. Simvastatin prevents vascular hyporeactivity during inflammation [published online ahead of print November 1, 2004]. Circulation. 2004;110:3349-3354. Available at: Accessed August 22, 2008.
Delbosc S, Morena M, Djouad F, Ledoucen C, Descomps B, Cristol JP. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes. J Cardiovasc Pharmacol. 2002;40:611-617.
BandohT, Sato EF, Mitani H, Nakashima A, Hoshi K, Inoue M. Antioxidative potential of fluvastatin via the inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity. Biol Pharm Bull. 2003;26:818-822.
Wagner AH, Köhler T, Rückschloss U, Just I, Hecker M. Improvement of nitric oxide–dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol. 2000;20:61-69. Available at: Accessed August 22, 2008.
Landry DW, Oliver JA. The pathogenesis of vasodilatory shock [review]. N Engl J Med. 2001;345:588-595.
Thomas L. Germs. N Engl J Med. 1972;287:553-555.
Warren HS. Strategies for the treatment of sepsis. N Engl J Med. 1997;336:952-953.
Hack CE, Zeerleder S. The endothelium in sepsis: source of and a target for inflammation. Crit Care Med. 2001;29(7 suppl):S21-S27.
Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med. 1996;24:163-172.
Bone RC. Why sepsis trials fail. JAMA. 1996;276:565-566.
Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment [review]. Crit Care Med. 1997;25:1095-1100.
Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Int Med 1994;120:771-783. Available at: Accessed August 22, 2008.
Bernard GB, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. Ibuprofen in Sepsis Study Group. N Engl J Med. 1997;336:912-918.
Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 1991;324:429-436.
Fein AM, Bernard GR, Criner GJ, Fletcher EC, Good JT Jr, Knaus WA, et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA. 1997;277:482-487.
Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653-658.
Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, et al; IL-1RA Sepsis Syndrome Study Group. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med. 1994;22:12-21.
Sharar SR, Winn RK, Murry CE, Harlan JM, Rice CL. A CD18 monoclonal antibody increases the incidence and severity of subcutaneous abscess formation after high-dose Staphylococcus aureus injection in rabbits. Surgery. 1991;110:213-219.
Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet. 1991;338:1557-1558.
Dhainaut JF, Tenaillon A, Le Tulzo Y, Schlemmer B, Solet JP, Wolff M, et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med. 1994;22:1720-1728.
Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of septic shock with tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med. 1996;334:1697-1720. Available at: Accessed August 26, 2008.
Reinhart K, Wiegand-Lohnert C, Grimminger F, Kaul M, Withington S, Treacher D, et al. Assessment of the safety and efficacy of the monoclonal antitumor necrosis factor antibody fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study [published correction appears in Crit Care Med. 1996;24:1608]. Crit Care Med. 1996;24:733-742.
Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA. 1995;273:934-941.
Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med. 1996;24:1125-1128.
Lederer JA, Rodrick ML, Mannick JA. The effects of injury on the adaptive immune response [review]. Shock. 1999;11:153-159.
O'Sullivan ST, Lederer JA, Horgan AF, Chin DH, Mannick JA, Rodrick ML. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg. 1995;222:482-492. Available at: Accessed August 22, 2008.
Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Proversus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis. 2000;181:176-180. Available at: Accessed August 29, 2007.
Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med. 1999;27:1230-1251.
Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature. 1997;390:350-351.
Le Tulzo Y, Pangault C, Amiot L, Guilloux V, Tribut O, Arvieux C, et al. Monocyte human leukocyte antigen-DR transcriptional downregulation by cortisol during septic shock [published online ahead of print March 17, 2004]. Am J Respir Crit Care Med. 2004;169:1144-1151. Available at: Accessed August 22, 2008.
Pangault C, Le Tulzo Y, Tattevin P, Guilloux V, Bescher N, Drénou B. Down-modulation of granulocyte macrophage-colony stimulating factor receptor on monocytes during human septic shock. Crit Care Med. 2006;34:1193-1201.
Fraunberger P, Pilz G, Cremer P, Werdan K, Walli AK. Association of serum tumor necrosis factor levels with decrease of cholesterol during septic shock. Shock. 1998;10:359-363.
Gordon BR, Parker TS, Levine DM, Saal SD, Wang JC, Sloan BJ, et al. Low lipid concentrations in critical illness: implications for preventing and treating endotoxemia. Crit Care Med. 1996;24:584-589.
van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med. 2003;31:1359-1366.
Engelberg H. Low serum cholesterol and suicide. Lancet. 1992;339:727-729.
Fraunberger P, Nagel D, Walli AK, Seidel D. Serum cholesterol and mortality in patients with multiple organ failure. Crit Care Med. 2000;28:3574-3575.
Read TE, Harris HW, Grunfeld C, Feingold KR, Kane JP, Rapp JH. The protective effect of serum lipoproteins against bacterial lipopolysaccharide. Eur Heart J. 1993;14(suppl K):125-129.
Gallin JI, Kaye D, O'Leary WM. Serum lipids in infection. N Engl J Med. 1969;281:1081-1086.
Harris HW, Grunfeld C, Feingold KR, Rapp JH. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest. 1990;86:696-702. Available at: Accessed August 22, 2008.
Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, et al. Structure and function of lipopolysaccharide binding protein. Science. 1990;249:1429-1431.
Mathison JC, Wolfson E, Ulevitch RJ. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest. 1988;81:1925-1937. Available at: Accessed August 22, 2008.
Netea MG, Demacker PN, Kullberg BJ, Jacobs LE, Verver-Jansen TJ, Boerman OC, et al. Bacterial lipopolysaccharide binds and stimulates cytokine-producing cells before neutralization by endogenous lipoproteins can occur. Cytokine. 1998;10:766-772.
McDonald MC, Dhadly P, Cockerill GW, Cuzzocrea S, Mota-Filipe H, Hinds CJ, et al. Reconstituted high-density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock. Shock. 2003;20:551-557.
Feingold KR, Grunfeld C. Lipoproteins: are they important components of host defense? Hepatology. 1997;26:1685-1686.
Figure 1.
The pharmacologic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (ie, statins), as indicated by the literature cited.
Figure 1.
The pharmacologic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (ie, statins), as indicated by the literature cited.
Figure 2.
The complex, variable characteristics of sepsis, also referred to as the “sepsis syndrome” and the “compensatory anti-inflammatory response syndrome.”
Figure 2.
The complex, variable characteristics of sepsis, also referred to as the “sepsis syndrome” and the “compensatory anti-inflammatory response syndrome.”